P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-10-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000891008.01210.7b |
| _version_ | 1827336209850957824 |
|---|---|
| author | Simonetta Viviani Anna Vanazzi Samuele Frassoni Chiara Rusconi Andrea Rossi Alessandra Romano Caterina Patti Corrado Schiavotto Roberto Sorasio Vincenzo Marasco Laura Lissandrini Davide Rapezzi Daniela Gottardi Federica Cocito Antonino Mulè Guido Gini Roberta Zanotti Alessandro Rambaldi Vincenzo Bagnardi Corrado Tarella |
| author_facet | Simonetta Viviani Anna Vanazzi Samuele Frassoni Chiara Rusconi Andrea Rossi Alessandra Romano Caterina Patti Corrado Schiavotto Roberto Sorasio Vincenzo Marasco Laura Lissandrini Davide Rapezzi Daniela Gottardi Federica Cocito Antonino Mulè Guido Gini Roberta Zanotti Alessandro Rambaldi Vincenzo Bagnardi Corrado Tarella |
| author_sort | Simonetta Viviani |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:28:03Z |
| format | Article |
| id | doaj.art-819c709ba34c4a1581604cde679adbb0 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:28:03Z |
| publishDate | 2022-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-819c709ba34c4a1581604cde679adbb02024-03-02T06:57:06ZengWileyHemaSphere2572-92412022-10-016515110.1097/01.HS9.0000891008.01210.7b202210005-00110P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centersSimonetta Viviani0Anna Vanazzi1Samuele Frassoni2Chiara Rusconi3Andrea Rossi4Alessandra Romano5Caterina Patti6Corrado Schiavotto7Roberto Sorasio8Vincenzo Marasco9Laura Lissandrini10Davide Rapezzi11Daniela Gottardi12Federica Cocito13Antonino Mulè14Guido Gini15Roberta Zanotti16Alessandro Rambaldi17Vincenzo Bagnardi18Corrado Tarella191 Division of Onco-Hematology, European Institute of Oncology, IRCCS, Milan, Italy1 Division of Onco-Hematology, European Institute of Oncology, IRCCS, Milan, Italy2 Department of Statistics and Quantitative Methods University of Milan-Bicocca, Milan, Italy3 SC Ematologia, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy4 Ematologia, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy5 Division of Haematology, Azienda Ospedaliera Policlinico-Vittorio Emanuele, University of Catania. Catania, Italy6 Division of Hematology 1 Azienda Ospedali Riuniti Villa Sofia-Cervello Palermo, Italy7 Ematologia, Presidio Ospedaliero S. Bortolo, Vicenza, Italy.8 Department of Hematology, S. Croce e Carle Hospital, Cuneo, Italy3 SC Ematologia, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy7 Ematologia, Presidio Ospedaliero S. Bortolo, Vicenza, Italy.8 Department of Hematology, S. Croce e Carle Hospital, Cuneo, Italy9 Divisione Universitaria di Ematologia e Terapie Cellulari, A.O. Ordine Mauriziano, Torino, Italy10 SC Ematologia, Ospedale San Gerardo, Monza, Italy6 Division of Hematology 1 Azienda Ospedali Riuniti Villa Sofia-Cervello Palermo, Italy11 Unit of Hematology, AUO Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy12 Divisione di Medicina, Unità di Ematologia, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.13 Ematologia, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo15 Department of Statistics and Quantitative Methods University of Milano-Bicocca, Milano, Italy16 Division of Onco-Hematology, European Institute of Oncology, IRCCS, Milan, Dipartimento Universitario di Scienze della Salute (DISS), Universita’ di Milano, Italyhttp://journals.lww.com/10.1097/01.HS9.0000891008.01210.7b |
| spellingShingle | Simonetta Viviani Anna Vanazzi Samuele Frassoni Chiara Rusconi Andrea Rossi Alessandra Romano Caterina Patti Corrado Schiavotto Roberto Sorasio Vincenzo Marasco Laura Lissandrini Davide Rapezzi Daniela Gottardi Federica Cocito Antonino Mulè Guido Gini Roberta Zanotti Alessandro Rambaldi Vincenzo Bagnardi Corrado Tarella P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers HemaSphere |
| title | P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers |
| title_full | P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers |
| title_fullStr | P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers |
| title_full_unstemmed | P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers |
| title_short | P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers |
| title_sort | p110 outcome of high dose chemotherapy hdct and autologous stem cell transplant asct as first salvage treatment for relapsed or refractory classical hodgkin lymphoma chl in the era of pet adapted strategy among italian centers |
| url | http://journals.lww.com/10.1097/01.HS9.0000891008.01210.7b |
| work_keys_str_mv | AT simonettaviviani p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT annavanazzi p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT samuelefrassoni p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT chiararusconi p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT andrearossi p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT alessandraromano p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT caterinapatti p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT corradoschiavotto p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT robertosorasio p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT vincenzomarasco p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT lauralissandrini p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT daviderapezzi p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT danielagottardi p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT federicacocito p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT antoninomule p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT guidogini p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT robertazanotti p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT alessandrorambaldi p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT vincenzobagnardi p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters AT corradotarella p110outcomeofhighdosechemotherapyhdctandautologousstemcelltransplantasctasfirstsalvagetreatmentforrelapsedorrefractoryclassicalhodgkinlymphomachlintheeraofpetadaptedstrategyamongitaliancenters |